These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15938592)

  • 1. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis.
    Wroe SJ
    J Int Med Res; 2005; 33(3):309-18. PubMed ID: 15938592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
    Gottesman MH; Friedman-Urevich S
    Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-β-1b: a review of its use in multiple sclerosis.
    Plosker GL
    CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
    O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
    Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.
    Gold R; Rieckmann P; Chang P; Abdalla J;
    Eur J Neurol; 2005 Aug; 12(8):649-56. PubMed ID: 16053475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation.
    Matson MA; Zimmerman TR; Tuccillo D; Tang Y; Deykin A
    Curr Med Res Opin; 2011 Dec; 27(12):2271-8. PubMed ID: 21988668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required.
    Prescrire Int; 2000 Aug; 9(48):110-1. PubMed ID: 11067719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.